Studies in vitro showed CPT1A deficiency in ovarian cancer cell lines results in decreased cellular ATP levels, cell cycle arrest, suppression of anchorage-independent growth, and reduced xenograft formation through the induction of p21 (cyclin-dependent kinase inhibitor) by activation of the transcription factor FoxO by AMPK, JNK, and p38 (194). The gene discussed is CPT1A; the disease is ovarian cancer.